Clinical Trial Update: Personalized Antisense Oligonucleotide Therapy for A Single Participant With ATN1 Gene Mutation [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial update describes a personalized antisense oligonucleotide therapy being studied for a single participant with Dentatorubral-Pallidoluysian Atro…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dentatorubral-pallidoluysian Atrophy

Drugs mentioned

• Personalized antisense oligonucleotide therapy for ATN1 mutation

Snippet

Sponsor: n-Lorem Foundation | Conditions: Dentatorubral-Pallidoluysian Atrophy | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING